In a landmark move for UK healthcare, pharmacy giant Boots has confirmed it will become the first high street chemist to offer private cannabis prescriptions. The service, branded as SureLeaf, marks a significant shift in how patients can access medicinal cannabis treatments.
Access and Eligibility
The new service will be available to patients aged 25 and over who suffer from chronic pain, insomnia, or generalised anxiety. To ensure patient safety, the programme includes strict clinical oversight:
* Prior treatment requirement: Patients must demonstrate they have already attempted traditional treatments without success. * Clinical screening: Boots clinicians will conduct video consultations and screen for disqualifying conditions, including a history of psychosis. * Ongoing care: The service will include monitoring of dosage and robust ongoing care for the 28-day prescription periods.
A New Chapter for Medicinal Access
While medicinal cannabis has been legal in the UK since 2018, access has remained notoriously difficult, often restricted to expensive private clinics. With millions of adults in the UK reporting chronic pain and insomnia, this move by a major high street retailer is expected to significantly improve accessibility.
Jamie Kerruish, Chief Healthcare Officer at Boots, stated: "Medical cannabis is a specialist area of healthcare and, through SureLeaf, we’re giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care."
This development follows the recent takeover of Boots by Canadian firm Whittington Investments. Given Canada’s long-standing experience with medicinal cannabis liberalisation, industry observers are watching closely to see if this signals a broader trend toward normalising cannabis-based medicines within the UK’s primary care infrastructure.
Source: LBC




